Copyright
©The Author(s) 2021.
World J Nephrol. May 25, 2021; 10(3): 29-36
Published online May 25, 2021. doi: 10.5527/wjn.v10.i3.29
Published online May 25, 2021. doi: 10.5527/wjn.v10.i3.29
Table 1 American College of Radiology manual classification of gadolinium-based agents relative to nephrogenic systemic fibrosis
| Group I: Agents associated with the greatest number of NSF cases: |
| Gadodiamide (Omniscan® – GE Healthcare) |
| Gadopentetate dimeglumine (Magnevist® – Bayer HealthCare Pharmaceuticals) |
| Gadoversetamide (OptiMARK® – Guerbet) |
| Group II: Agents associated with few, if any, cases of NSF: |
| Gadobenate dimeglumine (MultiHance® – Bracco Diagnostics) |
| Gadobutrol (Gadavist® – Bayer HealthCare Pharmaceuticals; Gadovist in many countries) |
| Gadoteric acid (Dotarem® – Guerbet, Clariscan – GE Healthcare) |
| Gadoteridol (ProHance® – Bracco Diagnostics) |
| Group III: Agents for which data remains limited regarding NSF risk, but for which few, if any cases of NSF have been reported: |
| Gadoxetate disodium (Eovist – Bayer HealthCare Pharmaceuticals; Primovist in many countries) |
- Citation: Bhargava V, Singh K, Meena P, Sanyal R. Nephrogenic systemic fibrosis: A frivolous entity. World J Nephrol 2021; 10(3): 29-36
- URL: https://www.wjgnet.com/2220-6124/full/v10/i3/29.htm
- DOI: https://dx.doi.org/10.5527/wjn.v10.i3.29